Lexaria Bioscience Corp. Annual report pursuant to Section 13 and 15(d)

Annual report pursuant to Section 13 and 15(d)

Common Shares and Warrants (Tables)

Common Shares and Warrants (Tables)

12 Months Ended

Aug. 31, 2021

Common Shares and Warrants

Represents the tabular disclosure of share issuance relating to option and warrant exercises.

Type of Issuance		Number of Shares				Total Value $
Warrant exercise			610,189				4,015,043
Private placement ⁽¹⁾			2,102,856				11,039,996
Per agreements⁽²⁾			12,178				85,000
			2,725,223				15,140,039

Type of Issuance		Number of Shares				Total Value $
Warrants exercised			-				-
Options exercised			7,333				30,030
Private placement ⁽¹⁾			356,332				2,859,916
Per agreements⁽²⁾			11,574				100,000
			375,239				2,989,946

Schedule of warrant

		Number of Warrants				Weighted Average Exercise Price $
Balance August 31, 2019			94,177				41.50
Cancelled/Expired			(25,000	)			45.00
Issued			402,431				12.74
Balance August 31, 2020			471,608				16.77
Cancelled/Expired			(44,161	)			67.50
Exercised			(610,189	)			6.58
Issued			2,630,017				6.58
Balance August 31, 2021			2,447,275				8.00

Schedule of Stockholders' Equity Note, Warrants or Rights, Valuation Assumptions

		August 31 2021				August 31 2020
Expected volatility		103%				91%-94%
Risk-free interest rate		0.16%				0.36%-2.87%
Expected life		3 years				2 – 5 years
Dividend yield			0	%			0	%
Estimated fair value per warrant		$6.51				$8.40 – $16.20

Schedule of warrants outstanding

Number of Warrants				Weighted Average Remaining Contractual Life			Weighted Average Exercise Price $
	61,090			0.20 – 3.25 years			36.00
	7,500			1.18 years			24.00
	317,190			3.68 – 3.70 years			10.50
	116,667			2.62 – 3.54 years			9.00
	200,000			2.62 years			7.00
	1,719,828			4.38 years			6.58
	25,000			0.11 years			4.20
	2,447,275			3.98 years			8.00